ABT stock forecast, quote, news & analysis

Key Takeaways

• Abbott Laboratories (ABT) declined roughly 12% over the trailing 30 days, pulling back from a mid-August peak near $116.64 to about $102.61.
• The retreat followed a strong July–August rally that was fueled by an earnings beat and a full-year guidance raise.
• Profit-taking, a $385 million Department of Justice settlement tied to an infant formula recall, and broader healthcare-sector pressure weighed on the stock in September.
• Over the trailing three months, ABT remains higher by roughly 17%, reflecting the strength of its second-quarter results and medical-device momentum.
• Analysts largely maintain a constructive view, with a consensus "Moderate Buy" rating and an average price target near $119.50.

Abbott Laboratories (ABT) Company Overview and Market Position

Abbott Laboratories is a diversified global healthcare company that develops, manufactures, and sells products across four principal segments: medical devices, diagnostics, established pharmaceuticals, and nutrition. Its device portfolio spans cardiovascular care, diabetes management, and electrophysiology, while its diagnostics business provides laboratory systems, tests, and point-of-care solutions. In nutrition, Abbott markets well-known consumer brands including Similac, Ensure, and Pedialyte, and its diabetes franchise is anchored by the FreeStyle Libre continuous glucose monitoring platform.

Abbott is widely followed by investors for its diversified revenue base, defensive characteristics, long track record of dividend payments, and a steady cadence of new product approvals in high-growth areas such as cardiac rhythm management and ablation. With institutional ownership above 75%, the stock is a core holding in many healthcare and dividend-oriented portfolios.

Abbott Laboratories (ABT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ABT declined approximately 12%, falling from a closing level of about $116.64 on August 21 to roughly $102.61 by September 18. The move marks a notable reversal after the stock had climbed steadily through July and much of August.

The broader quarterly picture tells a different story. Measured over the trailing three months, ABT remains up roughly 17%, having advanced from the high-$80s in late June to its August peak before giving back a portion of those gains in September. This pattern—a strong multi-month uptrend followed by a sharp short-term correction—illustrates how quickly sentiment can shift even for a fundamentally resilient, large-cap healthcare name.

What Drove ABT Stock Price in the Last 30 Days

The stock's August advance was supported by a strong second-quarter report released in mid-July. Abbott posted adjusted earnings of $1.31 per share, exceeding consensus estimates, on revenue of approximately $12.59 billion, up 13% year over year. Management also raised its full-year earnings guidance to a range of $5.45 to $5.60 per share, and the company received several analyst upgrades and price-target increases in the weeks that followed.

The September pullback reflected a combination of factors. Investors took profits after a sharp run-up, and the shares faced headwinds from a $385 million settlement with the U.S. Department of Justice related to an infant formula recall. Broader pressure across the healthcare and medical-device sector, along with a rotation in market sentiment, also contributed to the decline. Despite positive product news—including FDA approval for the TactiFlex Duo ablation catheter and progress in Abbott's electrophysiology pipeline—the stock moved lower as near-term uncertainty outweighed those catalysts.

What Drove ABT Stock Performance Over the Last Quarter

Over the trailing three months, ABT's overall gain was driven primarily by the strength of its second-quarter results and sustained momentum in its medical-device business. Electrophysiology and structural heart products delivered solid growth, supported by new launches and expanding adoption in international markets. The nutrition segment also showed improvement, with the pediatric business returning to growth and adult nutrition benefiting from earlier pricing actions.

At the same time, the company has continued to execute on its pipeline, advancing cardiovascular and diabetes innovations toward regulatory milestones. This multi-month narrative of earnings outperformance and product-cycle strength helped carry the stock higher through mid-August, even as September's legal settlement and profit-taking trimmed those gains. The quarterly trend therefore reflects a fundamentally positive backdrop punctuated by a sharp, sentiment-driven correction.

Trending AI Robots

For traders seeking a systematic approach to market moves like the one in ABT, Tickeron's Trending AI Robots page offers a curated look at AI-driven trading strategies. Tickeron provides hundreds of AI trading bots that trade thousands of tickers, yet only the top-performing and most relevant bots are featured in this dedicated section. These bots differ in strategy, timeframe, and performance metrics, allowing users to evaluate approaches that range from short-term momentum to longer-horizon trend following. The page is designed to help investors identify tools that align with their own trading style and risk tolerance, making it a useful starting point for those exploring algorithm-assisted investing.

ABT Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors will focus on Abbott's upcoming third-quarter earnings report and any updates to full-year guidance. Management has guided third-quarter earnings per share to a range of roughly $1.38 to $1.46, and the company's ability to sustain double-digit revenue growth will be a key test of sentiment.

Beyond earnings, the product pipeline remains central to the outlook. The continued rollout of the Volt pulsed field ablation catheter, adoption of the TactiFlex Duo system, and progress in Abbott's structural heart and diabetes franchises are expected to shape demand trends. On the macro side, healthcare-sector rotation, interest-rate expectations, and any additional developments related to the infant formula recall litigation could influence near-term price action. The company's dividend policy, recently maintained at $0.63 per share, also remains a focal point for income-oriented investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations